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Abstract
Arterial and venous thrombosis are major contributors to coagulation-associated morbidity and 
mortality. Greater understanding of mechanisms leading to thrombus formation and stability is 
expected to lead to improved treatment strategies. Factor XIII (FXIII) is a transglutaminase found 
in plasma and platelets. During thrombosis, activated FXIII crosslinks fibrin and promotes 
thrombus stability. Recent studies have provided new information about FXIII activity during 
coagulation and its effects on clot composition and function. These findings reveal newly-
recognized roles for FXIII in thrombosis. Herein, we review published literature on FXIII biology 
and effects on fibrin structure and stability, epidemiologic data associating FXIII with thrombosis, 
and evidence from animal models indicating FXIII has an essential role in determining thrombus 
stability, composition, and size.
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INTRODUCTION
Intravascular coagulation, or thrombosis, is a primary contributor to coagulation-associated 
morbidity and mortality. Thrombosis can occur in the arterial or venous circulation, leading 
to myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism. Arterial 
thrombosis is usually associated with atherosclerotic plaque rupture that exposes 
subendothelial cells and procoagulant material (e.g., tissue factor, collagen) to blood, leading 
to platelet activation and aggregation in high shear rates and stress. Ultimately, platelet 
accumulation and fibrin deposition produce an occlusive platelet-rich “white thrombus” 
(reviewed in1). In contrast, venous thrombosis/thromboembolism is thought to be triggered 
by inappropriate expression of cell adhesion molecules on intact, but dysfunctional 
endothelium in the presence of plasma hypercoagulability in reduced blood flow (stasis). 
This group of abnormalities is known as Virchow’s triad.2 Because venous thrombi have 
high red blood cell (RBC) content, they are known as “red thrombi.” Fibrin formation is a 
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central, etiologic component of both arterial and venous thrombosis, and is the ultimate 
target of thrombolytic enzymes used to treat both of these clinical presentations.
Factor XIII (FXIII) is a protransglutaminase found in cells and plasma. As the central driver 
of fibrin stability, the contribution of activated FXIII (FXIII[a]) to arterial and venous 
thrombosis has been investigated. However, although epidemiologic studies have associated 
abnormal FXIII levels and/or function with thrombosis risk, these associations are complex 
and the mechanisms by which FXIII contributes to thrombosis in vivo remain unclear.
Herein, we briefly review aspects of FXIII biology and activity. We then review recent 
findings on the contributions of these functions to thrombus formation, stability, and 
composition in vitro, and how these observations have exposed newly-recognized 
pathophysiologic roles for FXIII(a) during thrombosis in vivo. These discoveries may help 
reconcile apparently discordant findings from previous studies, and reveal new insight into 
the role of FXIII in arterial and venous thrombosis.
FXIII BIOLOGY
FXIII is one of 9 members of the transglutaminase superfamily found in both cellular 
(transglutaminases 1–7 and erythrocyte band 4.2) and plasma (pFXIII) compartments. The 
cellular forms of FXIII are present in multiple cell types, including monocytes, 
megakaryocytes, osteoblasts, and platelets (reviewed in3). Plasma and platelet FXIII are 
thought to contribute to blood coagulation.
FXIII in plasma
Plasma FXIII is unique because it circulates as two catalytic subunits (FXIII-A2) and two 
non-catalytic subunits (FXIII-B2) arranged in a non-covalent, heterotetramer (FXIII-A2B2, 
Mr 325-kDa, ~70 nM, 14–28 μg/mL).4 Mechanisms mediating the interactions between the 
A and B subunits are reviewed by Schroeder and Kohler in this issue of Seminars in 
Thrombosis and Hemostasis5. Essentially all FXIII-A2B2 zymogen circulates in complex 
with fibrinogen.6 Although older studies implicated the alternatively-spliced fibrinogen γ-
chain (termed γ′) in FXIII-A2B2 binding7,8, a more recent study using recombinant 
fibrinogen suggested FXIII-A2B2 binds both γA- and γ′-containing molecules with similar 
affinity (KD ~40 nM)9. Both older10 and more recent11 studies identified regions in the 
fibrinogen α-chain that bind FXIII. Smith et al.11 found that FXIII-A2B2 binds a peptide 
containing amino acid residues 371–425 of the fibrinogen αC domain with high affinity (KD 
5–30 nM). However, they did not demonstrate binding of FXIII-A2B2 to this region on full-
length fibrinogen and suggested that the interaction between FXIII-A2B2 and the αC region 
may arise during FXIII activation, and that other fibrinogen residues bind zymogen FXIII-
A2B2 in circulation.11 Our group showed that murine fibrin(ogen) containing alanine 
mutations within γ-chain residues γ390–396 (Fibγ390–396A) exhibits decreased binding of 
FXIII-A2B2, suggesting these residues mediate the carrier function.12 Since residues γ390–
396 are immediately N-terminal to the fibrin γ-chain residues that are crosslinked by FXIII 
(glutamine residues 398/399 and lysine 406), localization of FXIII-A2B2 at this site would 
position FXIIIa for rapid translocation to its nearby substrate recognition residues during 
thrombus formation.
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The interface of FXIII-A2B2 that interacts with fibrin(ogen) has not been determined. 
However, Souri et al.13 suggested the FXIII-B subunits augment the catalytic effect of 
fibrin(ogen) binding on FXIII activation. Further experiments using truncated FXIII-B 
subunits suggested sushi domains 1 and 10 mediate this interaction.13 More studies are 
needed to characterize the specific FXIII residues involved in the FXIII-fibrinogen 
interaction, and how these residues contribute to FXIII localization during thrombus 
formation.
FXIII in platelets
Platelet FXIII is a homodimer of catalytic subunits (FXIII-A2) present in high 
concentrations (~46–82 fg/platelet).14 Most platelet FXIII is derived from megakaryocytes 
during platelet production, but platelets may also uptake a minor fraction from plasma as 
fibrinogen-bound FXIII-A2B2. Platelets may also translate FXIII mRNA de novo.15 In 
unactivated platelets, FXIII-A2 is primarily associated with the cytoplasmic fraction.16
FXIII activation
During activation of plasma FXIII-A2B2, thrombin first catalyzes the cleavage of activation 
peptide(s) from the N-termini of the FXIII-A subunits (FXIII-A2′B2).17,18 Calcium then 
promotes dissociation of the FXIII-B subunits from FXIII-A2′, yielding activated FXIII-A2* 
(FXIIIa).19 Plasma FXIII activation occurs early during coagulation and is accelerated when 
it is bound to fibrinogen, which facilitates dissociation of the FXIII-B subunits.10,20,21 This 
function ascribes fibrin(ogen) with an important regulatory role during FXIII(a) activation 
and activity. Plasma from mice that have reduced binding of FXIII-A2B2 to fibrin(ogen) 
(Fibγ390–396A mice) exhibits delayed activation of FXIII-A2B2 and slower formation of 
fibrin γ- and α-chain crosslinks.12 In addition to demonstrating the catalytic role of FXIII-
A2B2 binding to fibrinogen in plasma, these findings led to new observations on the impact 
of FXIII activation kinetics on thrombus formation in vivo (discussed below).
Activation of platelet FXIII-A2 can occur after thrombin- or calpain-mediated cleavage of 
the activation peptide(s).22 FXIII-A2 can also be activated without activation peptide 
cleavage, in the presence of high calcium concentrations.23 Following platelet activation, 
FXIII-A2* is exposed in protruding caps on the surface of phosphatidylserine-positive 
platelets, but is not released into the supernatant.16 The mechanisms mediating FXIII 
exposure on activated platelets are still poorly-understood.
Although early studies suggested the activation peptide(s) remain bound to FXIII-A2*, more 
recent studies indicate the activation peptide is released during FXIII activation18,24 and can 
be used as a biomarker of acute ischemic stroke.25
FXIIIa inactivation
FXIIIa activity is generated early during clot formation and can still be detected within 
experimental thrombi 6 or more hours after the onset of clotting.26 Consequently, 
mechanisms mediating FXIIIa inactivation are of substantial interest. FXIIIa inactivation has 
been attributed to reversible oxidation, proteolytic digestion by thrombin, and proteolytic 
enzymes released by granulocytes.27,28 Studies have examined the ability of plasmin to 
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activate and inactivate FXIII(a)29,30, with conflicting conclusions. Recently, Hur et al. 
showed that both plasma- and platelet-derived FXIII-A2*, but not zymogen FXIII-A2B2, are 
cleaved by plasmin during fibrinolysis.31 The specificity of this mechanism for activated 
FXIII-A2* may stem from steric protection provided by the FXIII-B subunits when bound to 
FXIII-A2. This finding is interesting because it temporally-associates clot dissolution with a 
mechanism to inactivate any FXIIIa that may be released from the dissolving clot. Thus, this 
mechanism suggests the coagulation system maintains tight control over transglutaminase 
activity during hemostasis. It is therefore intriguing to speculate that reduced fibrinolytic 
activity could promote thrombosis by permitting prolonged transglutaminase activity and 
excessive crosslinking of proteins within the thrombus and the blood.
FXIIIA TRANSGLUTAMINASE ACTIVITY AND EFFECTS ON FIBRIN
Each FXIII-A subunit contains an active site (cysteine 314, histidine 373, and aspartate 396) 
that catalyzes the formation of intermolecular ε-N-(γ-glutamyl)-lysyl crosslinks. FXIII-
A2B2 does not compete with FXIII-A2* for binding to fibrin21, indicating these interactions 
are mediated by unique binding sites. However, apart from the specific residues that are 
crosslinked, the nature of the intermolecular interaction between FXIII-A2* and fibrinogen 
has not been resolved. Smith et al. showed that the structural cleft on FXIII-A2* that is 
exposed by thrombin-mediated cleavage and subsequent release of the FXIII activation 
peptide contains a recognition site for the fibrin(ogen) α-chain.24 A consensus recognition 
motif for FXIIIa substrates has not been identified, suggesting the interaction between 
FXIIIa and its substrates is mediated by substrate secondary and/or tertiary structure rather 
than primary amino acid sequence, and may involve a distinct exosite on the FXIIIa 
molecule.32,33
Cellular FXIII(a) (cFXIII[a]) crosslinks cellular and plasma proteins and regulates a variety 
of physiologic functions including phagocytosis and cell locomotion, osteoblast 
differentiation and matrix formation, and preadipocyte maturation and proliferation. The 
contributions of FXIIIa activity to these and other non-classical functions are reviewed by 
Schroeder and Kohler5.
Although FXIIIa has over 140 potential substrates in plasma34, it actually displays high 
substrate specificity during clot formation and is best characterized for its role in fibrin 
crosslinking. Briefly, during coagulation, thrombin cleaves N-terminal fibrinopeptides from 
the Aα- and Bβ-chains to produce fibrin monomers that polymerize into fibrin fibers (Figure 
1). FXIIIa catalyzes the formation of isopeptide bonds between glutamine residues 398/399 
and lysine 406 in the fibrin γ-chain and subsequently between glutamine and lysine residues 
in the α-chain (Figure 1). It is likely that the preference of FXIIIa for fibrin is at least partly 
mediated by its pre-localization on fibrinogen in circulation, in that fibrin(ogen) “delivers” 
FXIII(a) to the nascent clot.
Fibrin crosslinking has minor effects on global network structure, but substantial effects on 
the structure and function of individual fibers, and consequently, clot biochemical and 
mechanical stability, and clot composition (Figure 2).
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Effects of FXIIIa on fibrin structure
Crosslinking has little effect on gross fibrin network morphology, producing, at most, only a 
minor (~12%) increase in fibrin network density.35–39 In contrast, fibrin crosslinking 
substantially alters the structure of individual fibrin fibers by promoting protofibril coupling 
within the fiber, itself.40 This effect, which is specifically associated with the formation of 
α-chain-rich, high molecular weight (HMW) crosslinked species, causes fiber compaction. 
Compaction decreases the size of pores within individual fibers, with potentially important 
effects on the diffusion of molecules like tissue-type plasminogen activator (tPA) through the 
fibers and consequently, on fibrinolysis. Fiber compaction also promotes fiber stiffening, 
making fibers more resistant to deformation under low strain.40 Thus, the effect of FXIIIa on 
thrombus formation likely stems from its effects on the biochemical and biomechanical 
properties of individual fibrin fibers.
Effects of FXIIIa on fibrin resistance to fibrinolysis
FXIII(a) has critical anti-fibrinolytic functions during coagulation, mediated by its ability to 
crosslink antifibrinolytic proteins, including α2-antiplasmin41,42, thrombin activatable 
fibrinolysis inhibitor43, and type-2 plasminogen activator inhibitor44 to fibrin. This activity 
is mediated primarily by plasma FXIII-A2*. However, in situations in which the 
concentration of plasma FXIII is low (≤10%), platelet FXIII-A2* exposed on the platelet 
surface also promotes fibrin stability by crosslinking α2-antiplasmin to fibrin.16,45
Effects of FXIIIa on fibrin mechanical stability
FXIIIa-mediated crosslinking significantly increases the elastic modulus (stiffness) of both 
individual fibrin fibers46–48 and whole clot networks49, and is required to protect the clot 
against premature disruption or dissolution. Using a synthetic FXIII inhibitor and a patient-
derived antibody to selectively inhibit the formation of HMW crosslinked species yet permit 
γ-γ dimer formation, Ryan et al.50 showed that γ-chain crosslinking, alone, is insufficient to 
stiffen fibrin networks, and that the increased stiffness is correlated with the formation of α-
chain-rich, HMW crosslinked species.50 More recent studies using a recombinant fibrinogen 
mutated to eliminate γ-chain crosslinking sites confirmed that α-chain crosslinking is the 
primary contributor to clot stiffness and elasticity.37,51,52
Effects of FXIIIa on clot contraction
Several studies have examined the role of FXIII in platelet-mediated clot contraction, with 
discordant results. Whereas some investigators reported impaired retraction of FXIII-
deficient plasma clots53–55, others observed normal or even increased contraction of plasma 
and whole blood clots from FXIII-deficient humans and mice12,39,56–58. Some of the discord 
may stem from the use of a transglutaminase inhibitor, cystamine, that also reduces thrombin 
activity59 and therefore, may have indirectly reduced thrombin-mediated platelet activation. 
Other experimental differences that may account for these discordant findings have not been 
identified.
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Effects of FXIIIa on clot composition
Our group recently showed that FXIIIa-mediated crosslinking of fibrin is also a major 
determinant of thrombus RBC content.12,39 Briefly, reduced plasma FXIII or presence of a 
FXIII(a) inhibitor decreases RBC retention in contracted human whole blood clots.12 Whole 
blood from mice with full or partial deficiency in the FXIII catalytic A-subunit also show 
decreased retention of RBCs in contracted clots.12 These data are consistent with the 
“excessive red cell fallout” previously reported in a family with congenital FXIII 
deficiency56, and demonstrate a newly-recognized function for FXIII(a) during clot 
formation. Further work using recombinant fibrinogen variants that lack γ- or α-chain 
crosslinking residues, and FXIIIa inhibitor concentrations that preferentially block formation 
of α-chain-rich HMW crosslinked species versus γ-γ dimers associated this effect 
specifically with fibrin α-chain crosslinking.39 Given the effect of fibrin α-chain crosslinks 
on fibrin biophysical properties37,50–52, these data suggest FXIIIa promotes RBC retention 
in clots via its ability to increase fibrin elastic modulus and/or elasticity during clot 
contraction. Since clot contraction packs and deforms RBCs trapped within the clot and 
decreases clot permeability60, these data implicate FXIII activity as a major determinant of 
clot composition and function. The contribution of these effects to thrombosis in vivo is 
discussed below.
FXIII-ASSOCIATED ISOMERASE ACTIVITY
Some studies have suggested that members of the transglutaminase family are also 
associated with a protein disulphide isomerase (PDI) activity.61,62 The thiol isomerase 
family is part of the intracellular biosynthetic pathway during protein synthesis, but 
members of this family also have extracellular functions. Curiously, none of the 
transglutaminases carry the canonical isomerase catalytic motif (cysteine-X-X-cysteine, 
where X can be any one of a number of amino acids), suggesting the PDI-like activity may 
reside in a protein that associates with these transglutaminases. Since canonical PDIs 
contribute to thrombosis in mice and possibly humans (reviewed in63,64), the possibility that 
a FXIII-related thiol isomerase activity promotes thrombus formation warrants further 
investigation.
EPIDEMIOLOGIC DATA ON THE ROLE OF FXIII IN THROMBOSIS
Excellent reviews have summarized epidemiologic studies investigating the contribution of 
FXIII to arterial and venous thrombosis.65–67 In aggregate, findings suggest FXIII antigen, 
activity, and/or genotype influence thrombosis risk, at least in certain populations and 
clinical situations. Notably, however, these studies have shown considerable discordance. 
This discord is thought to reflect several as-yet incompletely-understood aspects of FXIII 
function that may have influenced conclusions. These potential aspects are discussed below.
First, early studies were confounded by the use of FXIII activity assays that were 
unknowingly influenced by the FXIII-A Val34Leu polymorphism present in ~25% of 
European Caucasians.68 This polymorphism causes accelerated release of the FXIII 
activation peptide, 2.5-fold earlier FXIII activation, and consequently, faster fibrin 
crosslinking in vitro.69–71 In certain assays, this accelerated activation erroneously appears 
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as increased FXIIIa activity, leading to poor correlation between FXIII antigen and activity 
and overestimation of the normal range for FXIIIa activity.71 Notably, however, even after 
this effect was recognized, findings from studies evaluating the association of the Val34Leu 
polymorphism with venous and arterial thrombosis have been inconsistent.70,72–78 Meta-
analyses of these studies suggest presence of the 34Leu allele offers significant, but modest 
protection against coronary artery disease (CAD, odds ratio (OR) 0.81, 95% confidence 
interval (95% CI) 0.70–0.92)79 and venous thromboembolism (OR 0.85, 95% CI 0.77–
0.95).80
Second, effects of the Val34Leu polymorphism are modulated by complex gene-
environment interactions that were not appreciated in early studies. For example, an analysis 
of 474 patients with deep vein thrombosis enrolled in the Leiden Thrombophilia Study 
(LETS) showed only a possible weak protective effect of Leu34 homozygosity in men (OR 
0.7, 95% CI 0.4–1.3).81 However, a subsequent analysis of the same samples that considered 
plasma fibrinogen level suggested slightly stronger protection in both men and women, 
especially in those over 45 years old (OR 0.4, 95% CI 0.2–1.0).82 Similarly, in a large 
prospective study (Norfolk cohort of the European Prospective Investigation in Cancer and 
Nutrition study [EPIC-Norfolk]), the Val34Leu variant was not broadly associated with risk 
of CAD. However, when fibrinogen levels were considered in the analysis, Leu34 
homozygotes in the lowest tertile of fibrinogen concentration had increased risk of 
developing CAD (OR 2.88, 95 CI 1.24–6.74, P=0.003), whereas those in the highest tertile 
of fibrinogen concentrations trended towards reduced risk of developing CAD (OR 0.47, 
95% CI 0.18–1.17, P=0.1).83 Similarly, in a high-risk Hungarian population, although 
presence of the Leu34 allele did not appear to alter the risk of coronary sclerosis or 
myocardial infarction (MI) in the general population, when patients with fibrinogen levels in 
the upper quartile (>4.6 g/L) were analyzed, the Leu34 allele was associated with protection 
against MI (OR 0.41, 95% CI 0.18–0.93).84 The proposed mechanism for this effect is 
interesting. In plasmas with normal fibrinogen levels, the Leu34 allele produces clots with 
thinner fibers and decreased permeability, whereas in plasmas with high fibrinogen, it 
produces clots with thicker fibers, and increased permeability and susceptibility to 
fibrinolysis.85 Since abnormal fiber thickness and altered clot permeability and stability are 
associated with increased thrombosis risk (reviewed in86), these observations indicate that 
both FXIII genotype and plasma fibrinogen concentration should be considered when 
calculating thrombosis risk in population studies.
Third, other FXIII polymorphisms that are not frequently incorporated into epidemiological 
analyses may also modulate the association between FXIII and thrombosis risk in certain 
populations. For example, the FXIII-A Tyr204Phe polymorphism has been associated with 
high (9-to-11-fold) increased risk for MI and ischemic stroke in a Dutch cohort87,88, 
although there was no association seen in a Brazilian population89. The FXIII-B*2 
polymorphism (His95Arg) primarily found in African populations is associated with 
accelerated dissociation of the B-subunit.90 This polymorphism was associated with mildly 
increased risk of venous thrombosis in Dutch Caucasians (OR 1.5, 95% CI 1.1–2.0)90, but 
not in Iranians91, and is not associated with CAD or MI in a Hungarian population92. The 
FXIII-B*3 polymorphism that predominantly occurs in Asians results in a novel splice 
acceptor site which replaces the final 10 residues of the C-terminus with 25 new residues 
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containing one additional acidic and two extra basic residues.93 In a Hungarian population, 
this FXIII-B*3 polymorphism results in lower FXIII activity and antigen levels and is 
protective against CAD and MI, but only in the presence of both high fibrinogen levels and 
the FXIII-A Leu34 allele (OR 0.23, 95% CI 0.06–0.85 and OR 0.10, 95% CI 0.02–0.53, 
respectively, adjusted for synergy).92 Together, these studies suggest that incorporating 
information about these alleles may refine interpretations on the contribution of FXIII to 
thrombosis in certain populations.
Fourth, the effect of FXIII on thrombosis risk also appears to reflect sex-specific factors that 
have not been considered in all studies, many of which were not powered to detect a 
modulating effect of sex. For example, in a Hungarian population, FXIII antigen correlates 
with moderately increased risk of MI (OR 1.999, 95% CI 1.051–3.765, P=0.03)94 and 
peripheral artery disease (PAD, OR 2.000, 95% CI 0.943–4.240, P=0.07)95 in women, but 
not men. Moreover, although FXIII activity is slightly increased in both male and female 
PAD patients compared to controls, FXIII activity in the upper tertile (>120%) is correlated 
with increased risk of PAD in women (OR 2.316, 95% CI 1.157–4.635, P=0.02), but not 
men.95 The effect of the Val34Leu polymorphism on risk may also be sex-specific; female, 
but not male, homozygotes for the Leu34 allele have increased risk of fatal atherothrombotic 
stroke.96 The sex-specific factors that mediate these differences have not been identified.
Finally, but importantly, the possibility that publication bias has inflated the apparent impact 
of FXIII antigen, activity, and/or genotype on thrombosis risk must be considered when 
evaluating these data in aggregate. A meta-analysis of 16 studies on the Val34Leu 
polymorphism suggested that smaller studies with negative findings are less frequently 
published than studies with positive findings.79 Thus, the relationship between FXIII and 
thrombosis risk may be weaker than it appears.
ANIMAL MODELS INVESTIGATING THE ROLE OF FXIII IN THROMBOSIS
Animal models are a useful tool for studying thrombosis in physiologically-relevant settings 
that lack the heterogeneity of human populations. Studies using animal models have 
revealed early and rapid contributions of FXIII(a) activity to clot formation, stabilization, 
and composition during thrombosis in vivo.
Contribution of FXIII to arterial thrombosis
Mouse models have been used to extend clinical observations and examine the association of 
cellular FXIII with arterial thrombosis. For example, Mansfield et al. detected increased 
levels of circulating FXIII in patients with type 2 diabetes relative to healthy controls.97 
Using mouse models of diabetes, Elgheznawy et al. subsequently associated calpain- and 
miR-223 dependent upregulation of platelet FXIII with increased ferric chloride-mediated 
carotid artery thrombosis.15 Although preliminary, these findings suggest FXIII is involved 
in thrombotic complications in diabetes. In addition, patients who experienced post-MI heart 
failure or death have lower FXIII levels at hospital admission and increased FXIII 
consumption 5 days after MI.98 Reduced FXIII levels are also associated with increased risk 
of ventricular rupture.99,100 Studies using mice to examine the mechanism of this association 
indicate the relationship between FXIII level and myocardial repair is causative; FXIII-
Byrnes and Wolberg Page 8
Semin Thromb Hemost. Author manuscript; available in PMC 2017 November 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
deficient mice die from left ventricular rupture within 5 days after MI, whereas wild type 
mice or FXIII-deficient mice infused with FXIII replacement have normal survival rates.100 
These data suggest FXIII plays a role in healing the infarcted area and that FXIII levels may 
be an early prognostic indicator during and immediately following acute MI. In addition, 
since reduced FXIII decreases survival after acute MI, this outcome may bias retrospective 
studies on the role of FXIII in MI.
Two studies used animal models to test the ability of FXIIIa inhibitors to reduce arterial 
thrombus stability. In a rabbit model of femoral artery thrombosis and tPA-mediated 
thrombolysis, administration of a FXIIIa inhibitor reduced thrombus weights more than 
administration of tPA, alone, and facilitated thrombolysis in 50% of treated rabbits.101 
Similarly, in a canine model of coronary artery thrombosis, FXIIIa inhibition accelerated 
reperfusion and reduced residual thrombus mass following tPA administration.102 Notably, 
in both models this effect was limited to animals pretreated with the FXIIIa inhibitor, and 
was not observed in animals infused with FXIIIa inhibitor after thrombus induction.101,102 
This finding suggests FXIII activation and crosslinking activity occur early during 
thrombogenesis. Accordingly, using a fluorescent peptide derived from α2-antiplasmin to 
probe for FXIIIa activity in mice, Jaffer et al.103 detected signal enhancement within 30 
minutes of thrombus induction, indicating early generation of FXIIIa activity during 
thrombogenesis.
Contribution of FXIII to venous thrombosis
Our group used mice to investigate the effect of FXIII on venous thrombosis in vivo. 
Consistent with ex vivo observations of reduced RBC retention in FXIII-deficient 
clots12,39,56, thrombi from FXIII-deficient mice are smaller than thrombi from wild type 
mice and have reduced RBC content.12 These findings indicate a central role for FXIII 
activity during venous thrombosis in vivo. Intriguingly, mice with normal levels of FXIII, 
but reduced binding of plasma FXIII-A2B2 to fibrinogen (Fibγ390–396A mice) phenocopy 
FXIII-deficient mice, producing smaller venous thrombi with reduced RBC content.12 
Notably, the loss of FXIII binding to fibrinogen in Fibγ390–396A mice delays, but does not 
abolish, FXIII activation and fibrin crosslinking12; Fibγ390–396A thrombi are fully-
crosslinked 24 hours after thrombus induction (M.M. Aleman and A.S. Wolberg, 
unpublished observation). These observations in mice suggest biological rationales for FXIII 
binding to circulating fibrinogen in vivo: 1) binding and localization to fibrin(ogen) 
facilitates delivery of FXIII to the nascent thrombus, 2) localization of FXIII on fibrin(ogen) 
accelerates FXIIIa activation during thrombogenesis, and 3) FXIII activation at the thrombus 
site spatially and temporally associates FXIIIa activity with an essential function thrombus 
contraction. These data suggest not only the generation, but also the timing, of FXIIIa 
activity is a critical determinant of venous thrombus composition and consequently, size.
Contribution of FXIII to thrombus stability
FXIIIa activity may also influence risk of embolization of both arterial and venous thrombi. 
Platelet FXIII-A mRNA is significantly lower in patients with non-valvular atrial fibrillation 
and thrombus embolization than in similar patients with left atrial appendage thrombus and 
no history of embolization.104 Accordingly, in mice, FXIIIa-mediated crosslinking of 
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plasma fibronectin into thrombi formed in mesenteric arterioles enhances platelet 
aggregation and increases the stability of platelet-rich thrombi.105–107 In a ferric chloride 
model of venous thrombosis, FXIII-deficient mice show increased embolization compared to 
wild type mice.108
Together, these observations demonstrate critical FXIIIa contributions at several steps during 
thrombosis.
CONCLUSIONS AND REMAINING QUESTIONS
FXIII is unique among coagulation proteins, not only in the nature of its enzymatic activity 
that crosslinks, rather than proteolyzes proteins, but also in its ability to directly impact both 
biochemical and biophysical properties of thrombi. In the almost 70 years since its first 
description as a “fibrin stabilizing factor109”, defining the role of FXIII in coagulation has 
been a fundamental goal. Growing data from biochemical, epidemiological, and animal 
model studies suggest FXIII(a) is an important determinant of thrombus composition and 
stability.
Recent findings have resolved several long-standing questions, but also exposed new ones. 
For example, studies examining the contributions of the Val34Leu polymorphism to clotting 
have revealed complex gene-environment interactions that mediate this activity. However, 
these studies used purified proteins and cell-free plasma systems. Given the newly-
recognized effect of FXIII activation kinetics on whole blood clot composition (RBC 
retention)12,39, what is the effect of the Val34Leu polymorphism in more physiologically-
relevant whole blood systems? Studies have shown that both plasma and platelet FXIII can 
contribute to clot stability in vitro.16,41–45 Do both of these pools contribute to clot 
composition and stability in vivo? Data from animal models show FXIII(a) contributes to 
thrombus size and stability and subsequent tissue repair. Is there a potential role for FXIII(a) 
inhibitors as a primary or adjunct approach for anticoagulation? Continued investigations of 
both basic FXIII biology and the effect of FXIII on thrombosis in humans and animal 
models are expected to uncover central information about these (patho)physiologic 
mechanisms.
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Figure 1. FXIIIa crosslinking during fibrin formation
Fibrinogen is a hexamer composed of 2 Aα- (purple), 2 Bβ- (blue), and 2 γ-chains (green). 
During coagulation, thrombin cleaves N-terminal fibrinopeptides from the Aα- and Bβ-
chains, producing fibrin monomers which polymerize into protofibrils and subsequently, 
fibers.110 FXIIIa increases clot stability by introducing ε-N-(γ-glutamyl)-lysyl crosslinks 
between residues in the γ- and α-chains of fibrin monomers within individual fibers. FXIIIa 
first introduces crosslinks between γ-chains (forming γ-γ dimers) and subsequently 
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between γ- and α-chains (forming high molecular weight species [γ-multimers, α-
polymers, and αγ-hybrids]).37,50–52
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Figure 2. Contributions of FXIIIa to clot biochemical and mechanical stability
FXIIIa crosslinking of plasma proteins [i.e. α2-antiplasmin, (α2-AP)] increases the 
resistance of the clot to fibrinolysis. Crosslinking of the fibrin α- (purple) and γ-chains 
(green) stiffens fibrin fibers and increases the mechanical stability of the clot. Increased 
mechanical stability renders the clot more resistant to shear forces. α-chain crosslinking 
enables RBC retention during clot contraction.39
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